Skip to Content

Moexipril Pregnancy and Breastfeeding Warnings

Moexipril is also known as: Univasc

Medically reviewed on Mar 8, 2017

Moexipril Pregnancy Warnings

Animal studies have failed to reveal evidence of embryo or fetal toxicity or teratogenicity. In humans, use of drugs that act on the renin angiotensin system (RAS) during the second and third trimesters increases fetal and neonatal morbidity and death. There are no controlled data in human pregnancy.

US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

UK: Use is not recommended during the first trimester of pregnancy and is contraindicated during the second and third trimesters.
US: This drug should not be used during pregnancy unless there are no alternatives and the benefit outweighs the risk to the fetus.

US FDA pregnancy category: D

Comments: Adequate methods of contraception should be encouraged.

See references

Moexipril Breastfeeding Warnings

UK: Use is not recommended.
US: Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Univasc (moexipril)." Schwarz Pharma, Mequon, WI.

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Univasc (moexipril)." Schwarz Pharma, Mequon, WI.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide